Background. Cellular markers of immune activation are strong predictors of disease progression and comorbidities in HIV infection. It is unclear whether soluble biomarkers of T cell (sIL-2r) and monocyte (MNC) activation (sCD14, sCD163) represent robust surrogate markers of cellular immune activation during the course of antiretroviral therapy (ART).
Methods. In the ACTG A5260s study, Spearman correlations between biomarkers of T-cell and MNC activation and proinflammatory MNC ( pMNCs) subsets were estimated at entry and 96 weeks in 328 HIV-infected treatment-naive subjects randomized equally to tenofovir/emtricitabine plus raltegravir or ritonavir-boosted atazanavir or darunavir. Analyses were restricted to 234 (71%) subjects who had HIV-1 RNA <50 copies/ml by week 24 and thereafter. Plasma and cellular immune markers were determined by ELISA and flow cytometry, respectively.
Results. sIL-2r and sCD163 were significantly associated with T cell activation (% CD38 + DR+ CD8 T cells) at entry and 96 weeks. sCD163 was also associated with both T cell activation and pMNCs (% CD14 + CD16+ MNCs) after successful ART. sCD14 was significantly associated with T cell activation and pMNCs only at entry. After 96 weeks of ART, sIL-2r and sCD14 were not associated with cellular markers of pMNCs ( Conclusion. There were modest associations between all plasma markers of immune activation and cellular markers of T activation in viremic subjects. However, after successful ART, only sCD163 had a modest association with cellular markers of T cell activation. Plasma markers of immune activation may reflect different immune activation pathways with differential dependence on viral replication vs immune dysregulation that is not reversed with viral suppression by ART.
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